Shanghai Jingze

Shanghai Jingze Biotech is a clinical-stage biopharmaceutical company based in China, specializing in the development and commercialization of high-end biologics, including biosimilars and innovative drugs. The company focuses primarily on ophthalmology, oncology, and reproductive health, with a robust pipeline led by late-stage candidates targeting VEGF-related eye diseases. Its lead program, JZB01, is an aflibercept biosimilar in Phase 3 clinical trials for indications such as wet age-related macular degeneration. Shanghai Jingze operates integrated R&D and manufacturing facilities in Shanghai and Nanjing to support its goal of providing affordable, high-quality biological therapies. The company has successfully raised multiple rounds of financing from prominent healthcare investors to advance its clinical programs toward commercialization.